Will FDA Budge On User Fee Hike Reductions? Stakeholders To Meet In May
This article was originally published in The Gray Sheet
Executive Summary
The current preoccupation with FDA postmarket safety on Capitol Hill could dispose legislators toward the agency's stance that year-over-year user fee hikes should not be held to the inflationary rate alone